Ins and Outs of cardiovascular gene therapy; CardioGene: The Inside; Eurogene: The outside

Gene therapy has two critical requirements: delivery of the gene vector to the appropriate tissues or location within the body, and expression of a gene product that has therapeutic benefit. Cardiovascular disease is thought to be an excellent opportunity since targeted delivery to blood vessels is easier than for other organs, and a number of genes relevant to cardiovascular indications have been identified.

CardioGene Therapeutics has both pieces of the puzzle: gene expression vectors with promising genes to deliver, and devices designed by the founding scientists/cardiologists to deliver those vectors specifically to blood vessels. The company is focused in restenosis, plaque stabilization, and angiogenesis to treat ischemia, aneurysm and heart failure.

Co-founders Elizabeth and Gary Nabel at the University of Michigan (Ann Arbor) have developed a

Read the full 1245 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE